Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
about
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.Enhancement in a brain glioma model: a comparison of half-dose gadobenate dimeglumine versus full-dose gadopentetate dimeglumine at 1.5 and 3 T.
P2860
Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@en
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@nl
type
label
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@en
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@nl
prefLabel
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@en
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@nl
P2093
P1433
P1476
Evaluation of the incidence of ...... adobenate dimeglumine for MRI.
@en
P2093
P304
P356
10.1016/J.CRAD.2009.04.004
P577
2009-05-26T00:00:00Z